Namit Chaudhary
Overview
Explore the profile of Namit Chaudhary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doerfler R, Yerneni S, LoPresti S, Chaudhary N, Newby A, Melamed J, et al.
FASEB J
. 2025 Jan;
39(2):e70340.
PMID: 39835705
Milk is a multifaceted biofluid that is essential for infant nutrition and development, yet its cellular and bioactive components, particularly maternal milk cells, remain understudied. Early research on milk cells...
2.
Chaudhary N, Kasiewicz L, Newby A, Arral M, Yerneni S, Melamed J, et al.
Nat Biomed Eng
. 2024 Oct;
8(11):1483-1498.
PMID: 39363106
Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicle for RNA therapeutics, partly because of established lipid structure-activity relationships focused on formulation potency. Yet such knowledge has not extended...
3.
Meany E, Klich J, Jons C, Mao T, Chaudhary N, Utz A, et al.
bioRxiv
. 2024 Jul;
PMID: 39026835
Messenger RNA (mRNA) delivered in lipid nanoparticles (LNPs) rose to the forefront of vaccine candidates during the COVID-19 pandemic due in part to scalability, adaptability, and potency. Yet there remain...
4.
Strelkova Petersen D, Weiss R, Hajj K, Yerneni S, Chaudhary N, Newby A, et al.
Adv Healthc Mater
. 2024 Jun;
13(22):e2400225.
PMID: 38888972
Lipid nanoparticles (LNPs) are proven safe and effective delivery systems on a global scale. However, their efficacy has been limited primarily to liver and immune cell targets. To extend the...
5.
Chaudhary N, Newby A, Arral M, Yerneni S, LoPresti S, Doerfler R, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(11):e2307810121.
PMID: 38437545
Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the...
6.
Doerfler R, Yerneni S, Newby A, Chaudhary N, Shu A, Fein K, et al.
PLoS One
. 2024 Jan;
19(1):e0297821.
PMID: 38295101
Recent data has characterized human milk cells with unprecedented detail and provided insight into cell populations. While such analysis of freshly expressed human milk has been possible, studies of cell...
7.
Chaudhary N, Newby A, Whitehead K
Small
. 2023 Dec;
20(41):e2306134.
PMID: 38145340
During pregnancy, the risk of maternal and fetal adversities increases due to physiological changes, genetic predispositions, environmental factors, and infections. Unfortunately, treatment options are severely limited because many essential interventions...
8.
Strelkova Petersen D, Chaudhary N, Arral M, Weiss R, Whitehead K
Eur J Pharm Biopharm
. 2023 Oct;
192:126-135.
PMID: 37838143
mRNA is a versatile drug molecule with therapeutic applications ranging from protein replacement therapies to in vivo gene engineering. mRNA delivery is often accomplished using lipid nanoparticles, which are formulated...
9.
Umei N, Shin S, Lai A, Miller J, Roberts K, Strelkova D, et al.
ASAIO J
. 2023 Feb;
69(6):527-532.
PMID: 36728837
Heparin anticoagulation increases the bleeding risk during extracorporeal life support (ECLS). This study determined whether factor XII (FXII) silencing using short interfering RNA (siRNA) can provide ECLS circuit anticoagulation without...
10.
Melamed J, Yerneni S, Arral M, LoPresti S, Chaudhary N, Sehrawat A, et al.
Sci Adv
. 2023 Jan;
9(4):eade1444.
PMID: 36706177
Systemic messenger RNA (mRNA) delivery to organs outside the liver, spleen, and lungs remains challenging. To overcome this issue, we hypothesized that altering nanoparticle chemistry and administration routes may enable...